Annual Reports in Medicinal Chemistry

Part I. Central Nervous System Diseases ¨C ROBICHAUD<br><br>Chapter 1 Recent Advances in Corticotropin Releasing Factor Receptor Antagonists<br>Carolyn D. Dzierba; Richard A. Hartz; Joanne J. Bronson<br><br>Chapter 2 Recent Advances on the 5-HT5A, 5-HT6 and 5-HT7 Receptors<br>Brock T. Shireman, Pascal Bonaventure and Nicholas I. Carruthers<br><br>Chapter 3 Recent Advances in Voltage Gated Sodium Channel Blockers: Therapeutic Potential as Drug Targets in the CNS<br>Andreas Termin, Esther Martinborough and Dean Wilson<br><br>Chapter 4 Medication Development for the Treatment of Substance Abuse<br>Brian Fulton <br><br><br>Part II. Cardiovascular and Metabolic Diseases - STAMFORD<br><br>Chapter 5 GPR40 (FFAR1) Modulators<br>Julio C. Medina and Jonathan B. Houze<br><br>Chapter 6 Rho-Kinase Inhibitors for Cardiovascular Disease<br>Robert A. Stavenger<br><br>Chapter 7 LXR Agonists for the Treatment of Atherosclerosis - Recent Highlights<br>Jonathan Bennett, Andrew Cooke, Heather J. McKinnon and Olaf Nimz<br><br>Chapter 8 Glucagon Receptor Antagonists for Type II Diabetes <br>DuaneE. DeMong, Michael W. Miller and Jean Lachowicz<br><br><br><br>Part III. Inflammation / Pulmonary / GI ¨C BARRISH<br><br>Chapter 9 Advances Towards Dissociated Non-Steroidal Glucocorticoid Receptor Agonists<br>John Regan, Hossein Razavi, David Thomson<br><br>Chapter 10 Advances in the Discovery of IkB Kinase Inhibitors<br>William J. Pitts and James Kempson<br><br>Chapter 11 Protease Inhibitors for the Potential Treatment of Chronic Obstructive Pulmonary Disease and Asthma <br>Weimin Liu and Eugene Hickey<br><br><br><br>Part IV. Oncology - MYLES<br><br>Chapter 12 mTor Inhibitors in Oncology<br>Jeroen Verheijen, Ker Yu and Arie Zask<br><br>Chapter 13 Oncology Drug Targets in the Sphingomyelin Signaling Path<br>Bill Garland, Amy Cavalli and Genevi¨¨ve Hansen<br><br><br>Part V. Infectious Diseases - Primeau<br><br>Chapter 14 Inhibitors of Respiratory Syncytial Virus <br>Malcolm Carter and G. Stuart Cockerill <br><br>Chapter 15 Recent Developments in ¦Â-Lactamases and Inhibitors<br>Tarek S. Mansour, Patricia A. Bradford and Aranapakam M. Venkatesan<br><br>Chapter 16 Recent Development in the Treatment of Clostridium Difficile Associated Disease (CDAD)<br>Xicheng Sun, Joseph Guiles and Nebojsa Janjic<br><br>Chapter 17 Recent Advances in the Discovery of Hybrid Antibacterial Agents<br>Mike Barbachyn<br><br><br>Part VI. Topics in Biology - LOWE<br><br>Chapter 18 Recent Renaissance of Prostaglandin Research<br>Robert Burk<br><br>Chapter 19 Human Exposure and Dose Projections<br>Punit H. Marathe, Christine Huang and A. David Rodrigues<br><br>Chapter 20 Modeling Networks of Glycolysis, Overall Energy Metabolism and Drug Metabolism under a Systems Biology Approach<br>Zoltan Sarnyai and Laszlo G. Boros<br><br> <br>Part VII. Topics in Drug Design and Discovery ¨C DESAI<br><br>Chapter 21 Contrasting the Gastrointestinal Tracts of Mammals: Factors that Influence Absorption<br>John DeSesso and Amy Lavin Williams<br><br>Chapter 22 The Emerging Utility of Co-Crystals in Drug Discovery and Development<br>Nicholas Meanwell<br><br>Chapter 23 Pregnane X Receptor: Prediction and Attenuation of Human CYP3A4 Enzyme Induction and Drug-Drug Interactions <br>Michael W. Sinz<br><br>Chapter 24 Formulation in Drug Discovery <br>Robert Strictly<br><br><br>Part VIII. To Market, To Market<br><br>Chapter 25 To Market, To Market - 2007<br>Shridhar Hegde and Michelle Schmidt